Glucose‐lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all‐cause mortality, cardiovascular events and cancer

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 4, 2015-04 ,pp. : 350-362

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes

By Herman Gary A.   Bergman Arthur   Yi Bingming   Kipnes Mark    

Current Medical Research and Opinion, Vol. 22, Iss. 10, 2006-10 ,pp. : 1939-1947

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study*

By Pratley Richard E.   Reusch Jane E.-B.   Fleck Penny R.   Wilson Craig A.   Mekki Qais  

Current Medical Research and Opinion, Vol. 25, Iss. 10, 2009-10 ,pp. : 2361-2371

Informa Healthcare

Access to resources Recommend Favorite

Predictive models for all‐cause and cardiovascular mortality in type 2 diabetic inpatients. A cohort study

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 4, 2015-04 ,pp. : 474-484

John Wiley & Sons Inc

Access to resources Recommend Favorite

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes

By Hanefeld Markolf   Herman Gary A.   Wu Mei   Mickel Carolyn   Sanchez Matilde   Stein Peter P.    

Current Medical Research and Opinion, Vol. 23, Iss. 6, 2007-06 ,pp. : 1329-1339

Informa Healthcare

Access to resources Recommend Favorite